Bronchiectasis is a chronic lung condition characterised by permanent, abnormal dilation and destruction of the bronchial walls. Once established, structural damage does not reverse — but with good management, progression can be slowed and quality of life maintained. As a CDL condition, medical aids must fund core medications. However, significant gaps exist in allied health coverage, physiotherapy access, and the funding of specialised inhaled antibiotic therapy for advanced disease.
What Is Bronchiectasis?
Bronchiectasis results from a recurring cycle of airway infection, inflammation, and structural damage. The damaged bronchial walls lose their normal mucus-clearing ability, trapping secretions and creating conditions for recurrent bacterial infection. This cycle perpetuates further damage.
Common causes in South Africa include: - Post-infectious: Following severe pneumonia, whooping cough (pertussis), or — particularly relevant in SA — pulmonary tuberculosis (TB). Post-TB bronchiectasis is a significant and often under-recognised burden. - Recurrent childhood pneumonias leading to structural airway changes - Primary ciliary dyskinesia (PCD): Rare genetic disorder; impaired ciliary function prevents normal mucus clearance - Immune deficiencies: Common variable immunodeficiency (CVID) and other primary immune defects predispose to recurrent pulmonary infections - Cystic fibrosis (CF): CF causes bronchiectasis through a distinct molecular mechanism (CFTR mutation); management overlaps substantially but important differences exist — notably, Pulmozyme (dornase alfa) is CF-specific and should not be assumed to be available or funded for non-CF bronchiectasis.
Key clinical features: - Chronic productive cough with large volumes of mucopurulent sputum — typically the most disabling daily symptom - Recurrent pulmonary exacerbations — defined deteriorations requiring antibiotic treatment, often 2–4 times per year in moderate-to-severe disease - Haemoptysis — coughing up blood; usually small-volume; large-volume haemoptysis is a medical emergency - Progressive airflow obstruction in moderate-to-severe disease - Pseudomonas aeruginosa colonisation — once established, a marker of severe, rapidly progressing disease requiring specialised inhaled antibiotic therapy
CDL Coverage
Bronchiectasis is a CDL condition. Long-term maintenance medications — including prophylactic azithromycin, mucokinetics, and bronchodilators — must be funded from the CDL benefit once registered. The entire statutory benefit for bronchiectasis rests on CDL registration, as there is no separate PMB minimum standard outside of this framework (except for acute, life-threatening exacerbations requiring hospitalisation, which fall under PMB).
Treatment Pathway
Airway clearance — the foundation of management: Daily airway clearance is the single most important non-pharmacological intervention in bronchiectasis. This includes chest physiotherapy, oscillating positive expiratory pressure (PEP) devices (flutter valves, Aerobika, acapella), and postural drainage. Without consistent airway clearance, secretions accumulate and infection cycles accelerate. The challenge for patients is that standard medical aid physiotherapy benefits (typically 10–20 sessions per year) are designed for post-operative rehabilitation — not for the daily chronic management that bronchiectasis requires.
Hypertonic saline (nebulised): 3–7% hypertonic saline helps thin and mobilise secretions and is a standard adjunct to airway clearance. Monthly cost: approximately R400–R600. Should be CDL-funded once registered.
Long-term antibiotic prophylaxis — azithromycin: Azithromycin 500mg three times weekly is the standard prophylactic regimen for patients with three or more exacerbations per year. In addition to its antibiotic properties, azithromycin has anti-inflammatory and immunomodulatory effects relevant to bronchiectasis pathology. The evidence base is well-established. Monthly cost: approximately R350–R450. Should be on most CDL formularies.
Inhaled antibiotic therapy for Pseudomonas aeruginosa colonisation: For patients with confirmed Pseudomonas aeruginosa colonisation (positive sputum cultures on two or more occasions, more than three months apart), inhaled tobramycin (TOBI, nebulised solution) or inhaled colistin (Promixin) is indicated. Monthly cost: R5,000–R10,000. These are high-cost medications that may not be on the scheme's CDL formulary; exceptional-needs authorisation is almost universally required. Inhaled antibiotic therapy in Pseudomonas-positive bronchiectasis is supported by ERS (European Respiratory Society) bronchiectasis guidelines.
Exacerbation treatment: Outpatient exacerbations: Oral amoxicillin-clavulanate, doxycycline, or ciprofloxacin (for Pseudomonas). Duration typically 14 days. Inpatient exacerbations: IV piperacillin-tazobactam, meropenem, or tobramycin (IV) for severe Pseudomonas exacerbations.
Dornase Alfa (Pulmozyme) — CF-Specific Limitation
Dornase alfa (Pulmozyme) is a DNase enzyme that breaks down viscous airway secretions. It is registered in SA for cystic fibrosis. Its use in non-CF bronchiectasis is not recommended in international guidelines (evidence shows no benefit and possible harm outside CF) and is off-label in SA. Do not expect CDL funding for Pulmozyme in non-CF bronchiectasis.
Medication Cost Summary
Estimated; SAHPRA SEP verification pending.
| Medication | Estimated Monthly Cost |
|---|---|
| Azithromycin 500mg (prophylactic, 3×/week) | R350–R450 |
| Hypertonic saline 7% (nebulised) | R400–R600 |
| Inhaled tobramycin (TOBI — Pseudomonas) | R7,000–R10,000 |
| Inhaled colistin (Promixin — Pseudomonas) | R4,500–R6,500 |
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Mild (airway clearance + occasional antibiotic courses) | R10,000 – R40,000 |
| Moderate (azithromycin + chest physio + exacerbation treatment) | R40,000 – R100,000 |
| Severe — Pseudomonas (inhaled antibiotics + recurrent IV admissions) | R100,000 – R250,000+ |
Gap Cover Relevance
Bronchiectasis generates gap cover exposure primarily through pulmonologist consultation shortfalls (ongoing specialist review) and in-hospital specialist shortfalls during admissions for severe exacerbations requiring IV antibiotics. For most patients, the gap OPL (~R220,000/year) is more than adequate for the typical exposure profile.
The Physiotherapy Problem
Bronchiectasis patients need more airway clearance physiotherapy than almost any other chronic respiratory condition — yet most plan physiotherapy benefits are designed around episodic post-operative rehabilitation, not chronic daily management. Key strategies for managing this gap:
- Ask your pulmonologist to write a CDL-specific motivation for extended physiotherapy access, citing the clinical necessity for ongoing airway clearance in CDL-registered bronchiectasis
- Ask whether a pulmonary rehabilitation programme provides access to additional physiotherapy sessions beyond the standard annual limit
- Consider investing in a home-use oscillating PEP device (R2,000–R5,000 once-off) to supplement and reduce dependence on clinic physiotherapy for daily maintenance
Talk to Eldon
See which plans pay for bronchiectasis →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).